Thoughts After Amylyx AMX0035 Committee: How Special Is ALS At FDA?

 
• By Michael McCaughan

An advisory committee rejection of the proposed ALS therapy AMX0035 amounts to a vote in favor of US FDA’s approach to the review. It also amounts to an implicit rejection of the idea that ALS merits unique approaches given the devastating nature of the illness.

Duck getting special treatment
Some disease categories seem to get special treatment from the US FDA. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers